Aqueous buffered solution containing BSA and ≤0.09 % sodium azide.
Agent conservateur
Sodium azide
Précaution d'utilisation
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Stock
4 °C
Stockage commentaire
Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. The antibody was conjugated to Alexa Fluor® 488 under optimum conditions, and unreacted Alexa Fluor® 488 was removed.
Peter, Gleixner, Cerny-Reiterer, Herrmann, Winter, Hadzijusufovic, Ferenc, Schuch, Mirkina, Horny, Pickl, Müllauer, Willmann, Valent: "Polo-like kinase-1 as a novel target in neoplastic mast cells: demonstration of growth-inhibitory effects of small interfering RNA and the Polo-like kinase-1 targeting drug BI 2536." dans: Haematologica, Vol. 96, Issue 5, pp. 672-80, (2011) (PubMed).
Polo-like kinase (PLK1) is a serine/threonine kinase with structural similarities to Drosophila's Polo kinase and the Cdc5p of Saccharomyces cerevisiae. Like its invertebrate counterparts, PLK1 activity is required for DNA synthesis and is regulated throughout the cell cycle. Furthermore, PLK1 is highly expressed in primary tumors. It associates with the mitotic spindle during mitosis suggesting that, in addition to its role during S phase, PLK1 may play a role during chromosome segregation. This is consistent with its potential role in cancer development. Threonine 210 (T210) is one of the major phoshorylation sites in activated PLK1 obtained from human mitotic cells. The K50-483 monoclonal antibody recognizes the phosphorylated T210 of human PLK1.